Bioventus (BVS) revenue breakdown
By segment, U.S. is the largest at 88% of fiscal 2025 revenue; International grew fastest, 5% a year over 3 years.
By product, Pain Treatments is the largest at 51% of fiscal 2021 revenue; Surgical Solutions grew fastest, 27% a year over 2 years.
Revenue by segment
Fiscal years, as Bioventus reports them in its 10-K filings; fiscal 2025 total $568M.
| Segments | 2022 | 2023 | 2024 | 2025 | Share |
|---|---|---|---|---|---|
| U.S. | $455M | $450M | $507M | $502M | 88% |
| International | $57M | $62M | $66M | $66M | 12% |
Revenue by product
Fiscal years, as Bioventus reports them in its 10-K filings; fiscal 2021 total $431M.
| Products | 2019 | 2020 | 2021 | Share |
|---|---|---|---|---|
| Pain Treatments | $182M | $171M | $222M | 51% |
| Restorative Therapies | $104M | $89M | $122M | 28% |
| Surgical Solutions | $55M | $61M | $88M | 20% |
Revenue by region
Fiscal years, as Bioventus reports them in its 10-K filings; fiscal 2025 total $568M.
| Regions | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Share |
|---|---|---|---|---|---|---|---|---|
| U.S. | $305M | $294M | $388M | $455M | $450M | $507M | $502M | 88% |
| International | $35M | $27M | $43M | $57M | $62M | $66M | $66M | 12% |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for BVS.
Open BVS in InvestinglyQuestions
Where does Bioventus make its money?
In fiscal 2025, by segment: U.S. $502M, International $66M.
From Bioventus's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.